Toll-like receptor agonists as third signals for dendritic cell-tumor fusion vaccines

Edward I Cho1, Chunrui Tan, Gary K Koski

  • 1Head and Neck Institute, Cleveland Clinic, Cleveland, Ohio, USA.

Head & Neck
|November 13, 2009
PubMed
Abstract

Insights

Therapeutic cancer vaccines combining dendritic cell (DC)-tumor fusion hybrids with Toll-like receptor (TLR) agonists significantly reduced melanoma metastasis in mice. This combination therapy proved more effective than fusion hybrids alone.

Area of Science:

  • Immunotherapy
  • Cancer Research
  • Cellular Biology

Background:

  • Dendritic cell (DC)-tumor fusion hybrids are being investigated for cancer therapy.
  • Toll-like receptor (TLR) agonists can modulate immune responses.

Purpose of the Study:

  • To evaluate the therapeutic efficacy of combining DC-tumor fusion hybrids with TLR agonists.
  • To assess the impact on melanoma metastasis in a murine model.

Main Methods:

  • DC-tumor fusion hybrids were generated via electrofusion.
  • Mice with pulmonary metastases received injections of fusion hybrids and TLR agonists (poly(I:C) and CpG).
  • Interleukin (IL)-12 production was measured using ELISA.

Main Results:

  • The combination of fusion hybrids and TLR agonists significantly reduced the number of metastases compared to controls and fusion hybrids alone.
  • ELISA revealed limited IL-12 production from DC-tumor fusion hybrids post-TLR stimulation.

Conclusions:

  • CpG and poly(I:C) as a third signal with fusion hybrids significantly reduce melanoma metastasis.
  • DC-tumor fusion hybrids are not a primary source of IL-12 secretion in this context.

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
T Cell Activation and Clonal Selection01:22

T Cell Activation and Clonal Selection

T cells are integral to our adaptive immune system, recognizing and effectively responding to foreign antigens. T cell activation and clonal selection are pivotal in orchestrating this immune response. This article elucidates these mechanisms, detailing the roles of cluster of differentiation (CD) markers, major histocompatibility complex (MHC) molecules, costimulatory signals, and the process of clonal selection.
Naive T cells that have not yet encountered an antigen express two primary CD...
Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...